<DOC>
	<DOC>NCT00597116</DOC>
	<brief_summary>A clinical study to assess if a new investigational drug is effective in treating malignant mesothelioma, compared to a chemotherapy treatment (Navelbine®). In this study the patients will be assigned by chance to receive either the new drug or a chemotherapy treatment (Navelbine®). Treatment will continue as long as the cancer does not worsen and the patient wishes to continue in the study. The study will recruit approximately 66 patients.</brief_summary>
	<brief_title>An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Diagnosed with mesothelioma Previously treated with only one course of chemotherapy for mesothelioma No previous treatment with vinorelbine No serious heart problems within the last 3 months Serious abnormal laboratory values Severe or uncontrolled disease or condition as judged by the Investigator Pregnant or breastfeeding women Other cancers within the last 5 years Major surgery or radiation therapy within 4 weeks prior to starting study therapy Receipt of any investigational agents within 30 days prior to commencing study treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Mesothelioma</keyword>
	<keyword>inoperable</keyword>
	<keyword>relapsed</keyword>
</DOC>